V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 320002738 | 320001621 | 1.67 | 52.3 | Curative (C) | 2016-08-25 | 2016-09-20 | Cisplatin + Docetaxel +Fluorouracil | 02 | Y | 320016311 | PEMBROLIZUMAB |
| 320002739 | 320001621 | 1.67 | 97.8 | Curative (C) | 2015-03-15 | 2015-04-01 | Cetuximab + Radiotherapy Load | 02 | N | 320016311 | CAPECITABINE + CARBOPLATIN |
| 320002740 | 320001622 | 0 | 78 | Adjuvant (A) | 2015-09-01 | 2015-09-26 | Cisplatin + Vinorelbine (IV) | N | N | 320016320 | CAPECITABINE + CISPLATIN |
| 320002741 | 320001622 | 1.65 | 57 | Palliative (P) | 2013-08-06 | 2013-08-19 | Cisplatin + Vinorelbine (IV) | N | N | 320016320 | BCG |
| 320002742 | 320001622 | 1.66 | 55.7 | Neo-adjuvant (N) | 2016-07-28 | 2016-08-08 | Carboplatin + Etoposide IV 3 day | N | N | 320016320 | ICON TRIAL |
| 320002743 | 320001623 | 1.7 | 72 | Palliative (P) | 2014-01-03 | 2014-01-04 | Cisplatin + Docetaxel +Fluorouracil | 2 | N | 320016334 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320002744 | 320001624 | 1.69 | 88.1 | Palliative (P) | 2016-12-08 | 2016-12-11 | Gemcitabine + RT pancreas | 2 | N | 320016342 | CARBOPLATIN + ETOPOSIDE |
| 320002745 | 320001625 | 1.71 | 71 | Adjuvant (A) | 2015-02-22 | 2015-02-23 | CISPLATIN + GEMCITABINE | null | null | 320016350 | BEP |
| 320002747 | 320001627 | 1.68 | 62.6 | Adjuvant (A) | 2015-08-20 | 2015-09-17 | BCG Intravesical | 2 | N | 320016358 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320002748 | 320001628 | 1.53 | 51 | Adjuvant (A) | 2012-08-30 | 2013-11-30 | BCG Intravesical | N | N | 320016361 | CARBOPLATIN + DOCETAXEL |
| 320002749 | 320001628 | 1.67 | 72.3 | Neo-adjuvant (N) | 2013-03-11 | 2013-03-12 | Cisplatin + Docetaxel +Fluorouracil | Y | null | 320016361 | CISPLATIN + FLUOROURACIL + RT |
| 320002750 | 320001628 | 1.74 | 73 | Palliative (P) | 2017-11-24 | 2017-12-13 | Pazopanib | N | N | 320016361 | CETUXIMAB |
| 320002751 | 320001628 | 1.58 | 78.2 | Palliative (P) | 2014-09-26 | 2014-10-11 | CISPLATIN + GEMCITABINE | N | N | 320016361 | CISPLATIN + ETOPOSIDE |
| 320002752 | 320001629 | null | null | Adjuvant (A) | null | 2015-10-03 | TIP | N | N | 320016380 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320002753 | 320001630 | 1.7 | 60 | Adjuvant (A) | 2016-04-21 | 2016-04-28 | CARBOPLATIN + RT | 02 | N | 320016382 | TEMOZOLOMIDE + RT |
| 320002755 | 320001632 | 1.59 | 81.1 | Palliative (P) | 2017-01-01 | 2017-01-22 | Carboplatin+Fluorouracil 4 or 5 day | N | N | 320016389 | TRIAL |
| 320002756 | 320001632 | 1.65 | 90 | Neo-adjuvant (N) | null | 2017-07-05 | Temozolomide + RT | 02 | N | 320016389 | CISPLATIN + GEMCITABINE |
| 320002757 | 320001633 | 1.56 | 61.1 | Curative (C) | 2015-07-19 | 2015-07-22 | Bevacizumab 7.5mg/kg | 01 | N | 320016407 | BEVACIZUMAB |
| 320002758 | 320001634 | 1.64 | 65.1 | Palliative (P) | 2017-06-23 | 2017-06-23 | CISPLATIN + ETOPOSIDE | null | N | 320016413 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320002759 | 320004872 | null | 51.65 | Curative (C) | 2013-09-11 | 2013-10-01 | Carboplatin + Pemetrexed | 02 | N | 320016427 | BEVACIZUMAB |
| 320002760 | 320004872 | 1.74 | 85.8 | Adjuvant (A) | 2016-10-14 | 2016-11-11 | Carbo F | N | N | 320016427 | CISPLATIN + GEMCITABINE |
| 320002761 | 320004872 | 1.61 | 63.8 | null | 2017-05-10 | 2017-05-23 | Bevacizumab+Carbo+Gemcitabine | N | N | 320016427 | CARBOPLATIN + ETOPOSIDE |
| 320002762 | 320001635 | 1.55 | 52.2 | null | 2016-02-21 | 2016-02-21 | Cisplatin + Gemcitabine (D 1 & 8) | 02 | N | 320016446 | CAPECITABINE + CISPLATIN |
| 320002763 | 320001636 | 1.67 | 72 | Curative (C) | 2017-08-05 | 2017-08-05 | Oxaliplatin + Modified de Gramont | Y | Y | 320016449 | EOX |
| 320002764 | 320001637 | 1.67 | 51.4 | Curative (C) | 2015-11-06 | 2015-11-09 | CISPLATIN + DOCETAXEL + FLUOROURACIL | 01 | null | 320016456 | ICON8B TRIAL |
| 320002765 | 320001638 | 1.73 | 73 | Neo-adjuvant (N) | 2015-04-05 | 2015-04-05 | Cetuximab + Radiotherapy Maint | N | N | 320016460 | EVEROLIMUS |
| 320002766 | 320004873 | 1.86 | 111.8 | Curative (C) | 2014-07-25 | 2014-08-20 | Trial Unspecified | 99 | Y | 320016470 | CETUXIMAB + RT |
| 320002767 | 320004873 | 1.78 | 71.3 | Curative (C) | 2016-09-03 | 2016-09-22 | Paclitaxel 7 day | N | N | 320016470 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320002768 | 320001639 | 1.78 | 60 | Palliative (P) | 2015-04-01 | 2015-04-05 | Fluorouricil + Folonic Acid (MdG) | 02 | N | 320016487 | CARBO + FLUOROURACIL |
| 320002769 | 320001640 | 1.68 | 57.4 | Adjuvant (A) | 2017-05-11 | 2017-06-01 | Trial Unspecified | 2 | N | 320016488 | CISPLATIN + GEMCITABINE |
| 320002770 | 320001640 | 1.86 | 61.4 | Palliative (P) | 2015-02-08 | 2015-02-08 | VIDE | N | N | 320016488 | CAPECITABINE + CISPLATIN + STREPTOZOCIN |
| 320002771 | 320001641 | 1.63 | 69 | Neo-adjuvant (N) | 2016-11-29 | 2016-12-07 | CARBOPLATIN + Cetuximab + FLUOROURACIL | N | N | 320016491 | CAPECITABINE |
| 320002772 | 320001642 | 1.56 | 75.4 | Palliative (P) | 2016-03-26 | 2016-03-27 | CISPLATIN + GEMCITABINE | 2 | N | 320016498 | CISPLATIN + GEMCITABINE |
| 320002773 | 320004875 | 1.73 | 90.35 | Palliative (P) | null | 2014-05-24 | Cetuximab+Cisplatin+FU (> Cycle 2) | null | null | 320016503 | PEMBROLIZUMAB |
| 320002774 | 320001643 | null | null | Neo-adjuvant (N) | 2013-05-09 | 2014-08-24 | CETUXIMAB + RT | 02 | N | 320016506 | EVEROLIMUS |
| 320002775 | 320004876 | 1.55 | 81 | Palliative (P) | 2017-08-22 | 2017-08-23 | Cetuximab 7 day (Cycle 1) | 02 | N | 320016525 | CARBOPLATIN + ETOPOSIDE |
| 320002776 | 320004876 | 1.57 | 57.3 | Palliative (P) | 2017-06-16 | 2017-06-20 | Cisplatin + Pemetrexed | 2 | N | 320016525 | VIDE |
| 320002777 | 320001644 | null | 25.9 | Disease modification (D) | 2016-09-19 | 2016-09-21 | STS Rhabdomyosarcoma RMS 2005 IVAVV | N | null | 320016542 | CARBOPLATIN + RT |
| 320002778 | 320001644 | null | 51.4 | Disease modification (D) | 2013-09-20 | 2013-10-12 | Trial Unspecified | N | N | 320016542 | NOT MATCHED |
| 320002779 | 320001644 | 1.7 | 64.25 | Neo-adjuvant (N) | null | 2017-11-24 | ICON8 TRIAL | null | null | 320016542 | TRIAL |
| 320002780 | 320001644 | 1.68 | 63.9 | Adjuvant (A) | null | 2017-12-11 | Bevacizumab 7.5mg/kg | null | null | 320016542 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 320002781 | 320001645 | 1.75 | 59.1 | Curative (C) | 2013-12-03 | 2013-12-14 | POUT TRIAL | N | N | 320016566 | CISPLATIN + GEMCITABINE |
| 320002782 | 320001646 | 1.75 | 79.4 | Neo-adjuvant (N) | 2018-01-12 | 2018-01-13 | BCG Intravesical | 2 | N | 320016568 | CAP |
| 320002783 | 320001647 | 1.67 | 71.5 | Curative (C) | 2015-03-25 | 2015-04-08 | ICON8 TRIAL | N | N | 320016569 | CAPE + CARBOPLATIN + CETUXIMAB |
| 320002784 | 320001648 | 1.6 | 95.5 | Palliative (P) | 2013-06-17 | 2013-06-19 | Cisplatin + Docetaxel +Fluorouracil | 2 | N | 320016570 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320002785 | 320004878 | 1.44 | 61 | Palliative (P) | 2017-12-23 | 2017-12-24 | CAP | Y | N | 320016571 | CARBO + FLUOROURACIL |
| 320002786 | 320001649 | 1.8 | null | Neo-adjuvant (N) | 2017-04-02 | 2017-04-13 | NB HRNBL-1 COJEC Ind COURSE A | null | N | 320016575 | NOT MATCHED |
| 320002787 | 320001650 | 1.56 | 55 | Palliative (P) | null | 2016-05-27 | CISPLATIN + GEMCITABINE | N | N | 320016576 | CISPLATIN + DOCETAXEL |
| 320002788 | 320001650 | 1.7 | 71.7 | Adjuvant (A) | null | 2013-08-13 | Cisplatin + Docetaxel +Fluorouracil | N | Y | 320016576 | PACLITAXEL |
| 320002789 | 320001650 | 1.53 | 69.1 | Palliative (P) | 2015-11-27 | 2015-12-02 | PEMBROLIZUMAB | 02 | N | 320016576 | ICON TRIAL |